PortalPublikationenVenetoclax combinations delay the time to deterioration of H...

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Standard

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. / Pratz, Keith W; Panayiotidis, Panayiotis; Recher, Christian; Wei, Xudong; Jonas, Brian A; Montesinos, Pau; Ivanov, Vladimir; Schuh, Andre C; DiNardo, Courtney D; Novak, Jan; Pejsa, Vlatko; Stevens, Don; Yeh, Su-Peng; Kim, Inho; Turgut, Mehmet; Fracchiolla, Nicola; Yamamoto, Kazuhito; Ofran, Yishai; Wei, Andrew H; Bui, Cat N; Benjamin, Katy; Kamalakar, Rajesh; Potluri, Jalaja; Mendes, Wellington; Devine, Jacob; Fiedler, Walter.

in: BLOOD CANCER J, Jahrgang 12, Nr. 4, 71, 20.04.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pratz, KW, Panayiotidis, P, Recher, C, Wei, X, Jonas, BA, Montesinos, P, Ivanov, V, Schuh, AC, DiNardo, CD, Novak, J, Pejsa, V, Stevens, D, Yeh, S-P, Kim, I, Turgut, M, Fracchiolla, N, Yamamoto, K, Ofran, Y, Wei, AH, Bui, CN, Benjamin, K, Kamalakar, R, Potluri, J, Mendes, W, Devine, J & Fiedler, W 2022, 'Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia', BLOOD CANCER J, Jg. 12, Nr. 4, 71. https://doi.org/10.1038/s41408-022-00668-8

APA

Pratz, K. W., Panayiotidis, P., Recher, C., Wei, X., Jonas, B. A., Montesinos, P., Ivanov, V., Schuh, A. C., DiNardo, C. D., Novak, J., Pejsa, V., Stevens, D., Yeh, S-P., Kim, I., Turgut, M., Fracchiolla, N., Yamamoto, K., Ofran, Y., Wei, A. H., ... Fiedler, W. (2022). Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. BLOOD CANCER J, 12(4), [71]. https://doi.org/10.1038/s41408-022-00668-8

Vancouver

Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. BLOOD CANCER J. 2022 Apr 20;12(4). 71. https://doi.org/10.1038/s41408-022-00668-8

Bibtex

@article{d6781c32e8ce437982e762fbf301518c,
title = "Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia",
abstract = "Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.",
keywords = "Antineoplastic Combined Chemotherapy Protocols/adverse effects, Bridged Bicyclo Compounds, Heterocyclic, Cytarabine/therapeutic use, Fatigue/etiology, Humans, Leukemia, Myeloid, Acute/drug therapy, Quality of Life, Sulfonamides",
author = "Pratz, {Keith W} and Panayiotis Panayiotidis and Christian Recher and Xudong Wei and Jonas, {Brian A} and Pau Montesinos and Vladimir Ivanov and Schuh, {Andre C} and DiNardo, {Courtney D} and Jan Novak and Vlatko Pejsa and Don Stevens and Su-Peng Yeh and Inho Kim and Mehmet Turgut and Nicola Fracchiolla and Kazuhito Yamamoto and Yishai Ofran and Wei, {Andrew H} and Bui, {Cat N} and Katy Benjamin and Rajesh Kamalakar and Jalaja Potluri and Wellington Mendes and Jacob Devine and Walter Fiedler",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = apr,
day = "20",
doi = "10.1038/s41408-022-00668-8",
language = "English",
volume = "12",
journal = "BLOOD CANCER J",
issn = "2044-5385",
publisher = "NATURE PUBLISHING GROUP",
number = "4",

}

RIS

TY - JOUR

T1 - Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

AU - Pratz, Keith W

AU - Panayiotidis, Panayiotis

AU - Recher, Christian

AU - Wei, Xudong

AU - Jonas, Brian A

AU - Montesinos, Pau

AU - Ivanov, Vladimir

AU - Schuh, Andre C

AU - DiNardo, Courtney D

AU - Novak, Jan

AU - Pejsa, Vlatko

AU - Stevens, Don

AU - Yeh, Su-Peng

AU - Kim, Inho

AU - Turgut, Mehmet

AU - Fracchiolla, Nicola

AU - Yamamoto, Kazuhito

AU - Ofran, Yishai

AU - Wei, Andrew H

AU - Bui, Cat N

AU - Benjamin, Katy

AU - Kamalakar, Rajesh

AU - Potluri, Jalaja

AU - Mendes, Wellington

AU - Devine, Jacob

AU - Fiedler, Walter

N1 - © 2022. The Author(s).

PY - 2022/4/20

Y1 - 2022/4/20

N2 - Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

AB - Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Bridged Bicyclo Compounds, Heterocyclic

KW - Cytarabine/therapeutic use

KW - Fatigue/etiology

KW - Humans

KW - Leukemia, Myeloid, Acute/drug therapy

KW - Quality of Life

KW - Sulfonamides

U2 - 10.1038/s41408-022-00668-8

DO - 10.1038/s41408-022-00668-8

M3 - SCORING: Journal article

C2 - 35443742

VL - 12

JO - BLOOD CANCER J

JF - BLOOD CANCER J

SN - 2044-5385

IS - 4

M1 - 71

ER -